89Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in HNSCC

Part of paid clinical trials in San Francisco, California.

Sponsor
Stanford University
Study ID
NCT05423197
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Head-and-neck Squamous Cell Carcinoma

Eligibility Criteria

Sex
ALL
Age
19 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • 89Zr-panitumumab IV — DRUG
    Subjects will be given a bolus of 1.0 mCi (range 0.8 - 1.2 mCi) of 89Zr-panitumumab before undergoing further standard of care diagnostic evaluation of the lesions
  • Panitumumab — DRUG
    Panitumumab 30mg will be given orally

Study Details

The purpose of this study is to determine the diagnostic utility of 89Zr-panitumumab to identify metastatic lesion(s) in subjects with head and neck squamous cell carcinoma (HNSCC).

Key Dates

Start date
Jun 30, 2026
Status verified
Jul 2025
Primary completion
Dec 31, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
60 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Active Comparator: panitumumab 30 mg
    Subjects will be given a 30mg of panitumumab
  • Experimental: 89Zr-panitumumab IV
    Subjects will be given 89Zr-panitumumab IV

Primary Outcome Measure

Sensitivity and Specificity of 89Zr-panitumumab [ Time Frame: Up to 1 year ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Stanford Cancer InstituteSan FranciscoCalifornia94305
Roan C Raymundo, BS
[email protected]
650-721-4071
Grace Yi
[email protected]
650-723-1423
Fred Baik, MD (PRINCIPAL_INVESTIGATOR)
Yu-Jin Lee, MD, MS (SUB_INVESTIGATOR)
Andrei Iagaru, MD (SUB_INVESTIGATOR)
Carina Aparici, MD (SUB_INVESTIGATOR)
Guido Davidzon, MD (SUB_INVESTIGATOR)
Farshad Moradi, MD, PhD (SUB_INVESTIGATOR)
Benjamin L Franc, MD, MS, MBA (SUB_INVESTIGATOR)
Jagruti Shah, MBBS (SUB_INVESTIGATOR)
Saad Khan, MD (SUB_INVESTIGATOR)
Dimitrios Colevas, MD (SUB_INVESTIGATOR)
Fred Baik, MD (SUB_INVESTIGATOR)
Chris Holsinger, MD (SUB_INVESTIGATOR)
Vasu Divi, MD (SUB_INVESTIGATOR)

Find similar trials in San Francisco, CA

By research site
Stanford Cancer Institute· San Francisco, CA

Related Studies